Get the Stockscreener App
4.3405
3.37%
-0.1095
Kalaris Therapeutics Inc stock is traded at $4.3405, with a volume of 15,788.
It is down -3.37% in the last 24 hours and up +10.54% over the past month.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
See More
Previous Close:
$4.45
Open:
$4.45
24h Volume:
15,788
Relative Volume:
0.05
Market Cap:
$80.89M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-46.45%
1M Performance:
+10.54%
6M Performance:
-40.53%
1Y Performance:
+0.00%
1-Day Range:
$4.30
$4.63
1-Week Range:
$4.33
$8.445
52-Week Range:
$2.14
$12.50
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
Name
Kalaris Therapeutics Inc
Sector
Industry
Phone
650-249-2727
Address
628 MIDDLEFIELD ROAD, PALO ALTO
Compare KLRS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
4.325 | 83.23M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
405.64 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.22 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
542.01 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
795.45 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
326.40 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-03-25 | Initiated | Raymond James | Strong Buy |
| Jul-23-25 | Resumed | Piper Sandler | Neutral |
| May-07-25 | Initiated | Leerink Partners | Outperform |
| Apr-08-25 | Initiated | William Blair | Outperform |
Kalaris Therapeutics Inc Stock (KLRS) Latest News
Identifying reversal signals in Kalaris Therapeutics Inc.2025 Market Overview & Breakout Confirmation Alerts - newser.com
Is Kalaris Therapeutics Inc. stock positioned for digital transformationJuly 2025 Review & Risk Controlled Stock Alerts - newser.com
Real time breakdown of Kalaris Therapeutics Inc. stock performanceQuarterly Profit Summary & Low Drawdown Trading Techniques - newser.com
Is Kalaris Therapeutics Inc. building a consolidation base2025 Market Trends & Low Risk High Win Rate Stock Picks - newser.com
Kalaris Therapeutics (NASDAQ:KLRS) Receives "Sell (E)" Rating from Weiss Ratings - MarketBeat
Custom watchlist performance reports with Kalaris Therapeutics Inc.Market Trend Summary & Daily Momentum Trading Reports - newser.com
Price action breakdown for Kalaris Therapeutics Inc.July 2025 Big Picture & Accurate Intraday Trading Signals - newser.com
Has Kalaris Therapeutics Inc. found a price floorJuly 2025 Pullbacks & Free Growth Oriented Trading Recommendations - newser.com
Wall Street Zen Upgrades Kalaris Therapeutics (NASDAQ:KLRS) to Hold - Defense World
Kalaris Therapeutics (NASDAQ:KLRS) Upgraded at Wall Street Zen - MarketBeat
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Short Interest Update - MarketBeat
Building trade automation scripts for Kalaris Therapeutics Inc.Market Activity Recap & Precise Entry and Exit Recommendations - newser.com
Kalaris Therapeutics Inc Stock Analysis and ForecastSupport and Resistance Levels & Free Realize Exceptional Returns - earlytimes.in
Kalaris Therapeutics (KLRS) Price Target Increased by 33.33% to 15.64 - Nasdaq
What drives Kalaris Therapeutics Inc stock priceResistance Zone Identification & Our Experts Decode Market Noise for You - earlytimes.in
Kalaris Therapeutics, Inc.'s (NASDAQ:KLRS) biggest owners are private equity firms who got richer after stock soared 24% last week - Yahoo Finance
Private equity firms in Kalaris Therapeutics, Inc. (NASDAQ:KLRS) are its biggest bettors, and their bets paid off as stock gained 24% last week - simplywall.st
What analysts say about Kalaris Therapeutics Inc stockInsider Trading Compliance & Free High Velocity Capital Growth - earlytimes.in
Why SLDP stock remains resilientQuarterly Earnings Summary & Community Consensus Stock Picks - newser.com
How to use Fibonacci retracement on Kalaris Therapeutics Inc.Weekly Investment Summary & Real-Time Market Sentiment Reports - newser.com
Jalen Brunson Opens Up on Knicks Role Shift Under Mike Brown - Berawang News
Short interest data insights for Kalaris Therapeutics Inc.2025 Stock Rankings & Real-Time Chart Pattern Alerts - newser.com
has kalaris therapeutics inc. found a price floorWeekly Stock Report & Low Volatility Stock Recommendations - newser.com
Published on: 2025-09-22 09:09:39 - newser.com
What candlestick patterns are forming on Kalaris Therapeutics Inc.2025 Investor Takeaways & Real-Time Chart Breakout Alerts - newser.com
Kalaris enrolling phase 1b/2 study of TH103 for nAMD - Modern Retina
Measuring Kalaris Therapeutics Inc.’s beta against major indicesEarnings Beat & Target Return Focused Picks - newser.com
Technical signs of recovery in Kalaris Therapeutics Inc.2025 Major Catalysts & Breakout Confirmation Trade Signals - newser.com
Wall Street Recap: Should you avoid Kalaris Therapeutics Inc stock right nowProfit Target & Safe Swing Trade Setup Alerts - خودرو بانک
Earnings Risk: Is Kalaris Therapeutics Inc. a strong candidate for buy and holdJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - خودرو بانک
Moving Averages: Is Kalaris Therapeutics Inc. a speculative investmentWeekly Trade Recap & Community Trade Idea Sharing - خودرو بانک
Take Profit: Is YCBD a turnaround storyJuly 2025 Catalysts & Safe Entry Trade Signal Reports - khodrobank.com
Long term hold vs stop loss in Kalaris Therapeutics Inc.July 2025 Drop Watch & Daily Stock Trend Reports - newser.com
Will Kalaris Therapeutics Inc. benefit from macro trends2025 Bull vs Bear & Risk Adjusted Buy and Sell Alerts - newser.com
CEO Moves: Is Digi International Inc stock a value trapJuly 2025 Retail & Weekly Hot Stock Watchlists - khodrobank.com
Market Trends: Is Kalaris Therapeutics Inc. a strong candidate for buy and holdQuarterly Earnings Report & Free Community Consensus Stock Picks - خودرو بانک
Applying chart zones and confluence areas to Kalaris Therapeutics Inc.July 2025 EndofMonth & Weekly Setup with High ROI Potential - newser.com
MACD Signal: Should you avoid Kalaris Therapeutics Inc stock right nowIPO Watch & Long Hold Capital Preservation Tips - خودرو بانک
What the charts say about Kalaris Therapeutics Inc. today2025 Market Trends & Fast Entry Momentum Trade Alerts - newser.com
Volume spikes in Kalaris Therapeutics Inc. stock – what they mean2025 Investor Takeaways & Long-Term Safe Investment Plans - newser.com
Chart based exit strategy for Kalaris Therapeutics Inc.2025 Breakouts & Breakdowns & Technical Confirmation Alerts - newser.com
Using RSI to spot recovery in Kalaris Therapeutics Inc.2025 Short Interest & Long-Term Growth Portfolio Plans - newser.com
Visual trend scoring systems applied to Kalaris Therapeutics Inc.July 2025 Volume & Free Community Consensus Stock Picks - newser.com
Visualizing Kalaris Therapeutics Inc. stock with heatmapsWeekly Profit Report & Free Real-Time Volume Trigger Notifications - newser.com
Earnings visualization tools for Kalaris Therapeutics Inc.July 2025 Action & Risk Controlled Stock Alerts - newser.com
Kalaris Therapeutics Inc Stock (KLRS) Financials Data
There is no financial data for Kalaris Therapeutics Inc (KLRS). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
2.36%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):